O T C
Gold River Productions, Inc. (GRPS) announces its initial product line for physicians and its newly-initiated physician-patient distribution network

  Palm Coast, FL, April 5, 2021, Gold River Productions, Inc. (OTC Pink: GRPS) announces today its initial product line for physicians and its newly-initiated physician-patient distribution network. With RushNet Inc.’s (OTC Pink: RSHN) recent acquisition of HeliosDX, the Company isfortunate to share an expanding network of physicians through whom they will be marketing most of their products.

Chattahoochee Labs/HeliosDx announces the acquisition of control of a public entity, RushNet Inc. (OTC US: RSHN) and has filed with the State of Colorado

Alpharetta, Ga. March 30, 2021 – OTC PR WIRE – Chattahoochee Labs/HeliosDx has taken a major step forward in achieving its goal of robust and profitable expansion as well as adding exceptional value to its shareholders and announces the acquisition of public entity RushNet, Inc (OTC Pink: RSHN). Having enjoyed rapid growth in revenues from

UAT Group Inc, Acquires 20% of Next Casting Technologies

  Tampa FL, March 4th,2021 – OTC PR WIRE – Umbra Applied Technologies Group, Inc (OTC Pink: UATG) announced today that it has purchased 20% of the Austin, Texas based medical company Next Casting Technologies. The global orthopedic casting, splinting, braces and support market was valued at US $4.6 billion in 2015 and is expected

PAOG Confirms Cannabis Biopharmaceutical Strategic Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

Sandusky, OH, January 12, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today confirmed an update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts,

PAOG Takes Major CBD Pharmaceutical Development Step Forward

  Sandusky, OH, January 5, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product. PAOG today announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough Massachusetts.  PAOG has engaged Veristat to assist in advancing

RENAVOTIO, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2020

Tulsa, OK, November 17, 2020 – OTC PR WIRE — Renavotio, Inc (OTC US: RIII), (“Renavotio,” or the “Company”) today announced its recently-filed unaudited financial results for the third quarter ended September 30, 2020. For further information, please refer to the Company’s recently-filed 10Q on EDGAR. Revenue– Due to a new focus on domestic U.S.

Nutra Pharma Provides Financing Updates and the Elimination of Institutional Debt

Nutra Pharma is providing updates regarding debt restructuring and financing plans   Plantation, Florida, November 4, 2020 — OTC PR WIRE — Nutra Pharma Corporation (OTC PINK: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS),

PAOG Advances Nutraceutical Development From Its Cannabis Pharmaceutical Research

Sandusky, OH, October 29, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced adding a nutraceutical development pathway to its existing pharmaceutical cannabis drug development strategy.  Last week, PAOG announced a master services agreement with a clinical research organization (CRO) in the U.S. to prepare PAOG for initiating an investigational

PAOG Targets Spring Launch Of Hemp Cultivar Facility

Sandusky, OH – October 13, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today confirmed an agreement with Puration, Inc. (OTC PINK: PURA) to build a proprietary hemp cultivar development facility on PURA’s Farmersville, Texas branded site and announced an April 2021 target date for construction to be completed. PAOG recently

PAOG Engages Saul Kaye, Founder of iCAN: Israel-Cannabis and CannaTech To Prepare RespRx For IND

Sandusky, OH – October 1, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced engaging Saul Kaye the founder of iCAN (www.israel-cannabis.com) and CannaTech (www.canna-tech.co) to provide an independent review of PAOG’s RespRx research for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and to help prepare RexpRx for engaging

Recent Posts

Recent Posts

Contact Us

All Rights Reserved © 2019